A 2023 study by Song et al. assessed Niaoduqing granules for diabetic kidney disease, reporting a mean reduction in serum creatinine, BUN, and urinary albumin excretion rate alongside increased CCR with combined therapy—consistent with our observations for Bailing capsules (54). Here, ALB is linked to diabetic kidney disease.